Table 3 Toxicity per patient (Phase II)

From: Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

 

Grade 2

Grade 3

Grade 4

 

N (%)

N (%)

N (%)

Haematologic toxicity

Anaemia

8 (14.8)

2 (3.7)

0 (0.0)

Thrombocytopenia

2 (3.7)

0 (0.0)

0 (0.0)

Neutropenia

6 (11.1)

10 (18.5)

9 (16.7)

Febrile neutropenia

0 (0.0)

2 (3.7)

1 (1.9)

Lipase

2 (3.7)

0 (0.0)

1 (1.9)

Cutaneous toxicity

Hand-foot syndrome

5 (9.3)

7 (13.0)

0 (0.0)

Rash, erythema

4 (7.4)

0 (0.0)

0 (0.0)

Gastrointestinal toxicity

Anorexia

18 (33.3)

7 (13.0)

0 (0.0)

Diarrhoea

19 (35.2)

20 (37.0)

0 (0.0)

Nausea

12 (22.2)

3 (5.6)

0 (0.0)

Vomiting

8 (14.8)

2 (3.7)

0 (0.0)

Mucositis

4 (7.4)

4 (7.4)

0 (0.0)

Other

Asthenia

20 (37.0)

12 (22.2)

0 (0.0)

Back to article page